B. Riley Securities Initiates Coverage of Precigen at Buy
Fintel reports that on September 25, 2026, B. Riley Securities initiated coverage of Precigen (NASDAQGS:PGEN) (DB:I5X) with a Buy recommendation.
Precigen, Inc. is a biotechnology company based in the United States, primarily engaged in the development of gene and cell therapies. The company specializes in designing and producing synthetic biology solutions aimed at improving the quality of life by treating serious diseases. Its proprietary technology platform facilitates the production of innovative therapeutic candidates, including a diverse pipeline targeting conditions such as cancer, metabolic disorders, and infectious diseases. Key projects include CAR-T therapies for oncology, where the company is a significant player in advancing treatments that genetically engineer patients' immune cells to fight cancer more effectively. Precigen's combination of cutting-edge science and strategic collaborations underscores its role as a leader in the biotech industry, focusing on transformative and scalable therapeutic options.
On the rating action date of September 25, 2026, the latest close for Precigen was $7.75. The pre-action close on September 24, 2026, was $7.70. The price change one week percent was -0.39%, with a price change one week baseline close of $7.78 on September 18, 2026. The price change one month percent was +6.46%, with a price change one month baseline close of $7.28 on August 25, 2026.
Precigen reported its latest earnings on August 4, 2026. The company's latest earnings eps actual was 0.05, compared to the latest earnings eps estimate of -0.0136. The latest earnings revenue actual was $54,978,000.00, and the latest earnings revenue estimate was $28,389,996.00.
Separately from the individual rating by B. Riley Securities, the current consensus target mean for Precigen was $14.79 as of September 15, 2026, which is identical to the current consensus target median of $14.79. The current consensus target implied change percent was +90.84%. The prior consensus target mean was $14.79 as of August 28, 2026, with a consensus target revision percent of 0.00%.
For the current recommendation period as of September 1, 2026, the current recommendation total was 9. This total consists of 2 strong buy, 5 buy, 2 hold, 0 sell, and 0 strong sell recommendations. The current recommendation positive percent was 77.8%, the current recommendation hold percent was 22.2%, and the current recommendation negative percent was 0.0%. For the prior recommendation period as of August 1, 2026, the prior recommendation total was 9, consisting of 2 strong buy, 5 buy, 2 hold, 0 sell, and 0 strong sell recommendations, with a prior recommendation positive percent of 77.8%, a prior recommendation hold percent of 22.2%, and a prior recommendation negative percent of 0.0%.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 25, 2026 | B. Riley Securities | Buy | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.